# Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Source: https://onco.cc/key-papers/paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021/  
OnCo record `paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The 2021 journal summary of the US NCCN pancreatic cancer guideline, focused on drug treatment for disease that has spread locally or to other organs.

## Summary

Journal summary of the NCCN Clinical Practice Guidelines for Pancreatic Adenocarcinoma, version 2.2021, by Tempero, Malafa, Al-Hawary and colleagues. The abstract notes that pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States, that advanced disease at diagnosis remains the major challenge, and that survival rates remain relatively unchanged although newer modalities including targeted therapies provide hope. This manuscript focuses on the available systemic therapy approaches for locally advanced and metastatic disease. Earlier summaries (version 2.2017, version 1.2019 on adjuvant treatment) are on Europe PMC under the same title stem.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Tags: pancreatic-evidence
- Journal: Journal of the National Comprehensive Cancer Network
- Year: 2021
- DOI: 10.6004/jnccn.2021.0017
- Authors: Tempero MA, Malafa MP, Al-Hawary M, et al.
- Findings: Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States.; The summary concentrates on systemic therapy for locally advanced and metastatic disease.
- What it means: NCCN is the source of the category grades on the pancreatic cancer page and the guideline that first placed germline testing for every patient and universal tumour profiling in routine care.
- Caveats: The full guideline requires free registration on nccn.org; the JNCCN article is a summary and the live guideline has moved on several versions since.; US practice and payer context; not all listed options are funded in the UK.

## Sources

- JNCCN 2021: https://doi.org/10.6004/jnccn.2021.0017
- PubMed: https://pubmed.ncbi.nlm.nih.gov/33845462/
- NCCN Guidelines: Pancreatic Adenocarcinoma: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455

## Connected records

- collections: [NCCN Guidelines](https://onco.cc/collections/nccn/)
- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- journals: [Journal of the National Comprehensive Cancer Network](https://onco.cc/journals/jnccn/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021.json